Should You Buy Oracle Stock Despite Soft Guidance?

Spread the love

Oracle Corporation (NYSE: ORCL) is trading in extended trading after reporting better-than-expected results for its second fiscal quarter.

Oracle’s guidance for the third quarter

Shares held steady despite the multinational’s guidance for profit falling slightly shy of Street estimates.

Are you looking for breaking news, hot tips and market analysis?

For the current quarter, adjusted EPS ranged from $1.17 to $1.21 and analysts were expecting $1.23 per share. However, Daniel Morgan of the Synovus Foundation says Oracle Corp. is a good choice for stability in a challenging macroeconomic backdrop.

I expect Oracle to be well positioned in 2023. It trades at 15 times earnings, so its multiple is very low. They have a large install base, so their income is recurring, so they generate a lot of cash flow.

For the year, Oracle stock is down more than 5.0% on writedowns.

Oracle’s cloud revenue is growing rapidly

Earlier this year, Oracle spent about $28 billion on acquisitions Cerner Corporation – A health technology company. According to Morgan, that acquisition will also be significantly accretive to earnings.

According to the earnings report, cloud revenue was up 43% this quarter, and he expects that growth to continue. Talking to people in Yahoo Finance Morgan said:

The transition to Oracle’s leading role in the cloud space remains the same. It has more than 400,000 customers and only 35% have switched to using their cloud service products. Hence, there is a tremendous opportunity to transform the existing site.

Wall Street also has a consensus “Overweight” rating on Oracle shares.

Oracle reports strong second-quarter results

  • Earned $1.74 billion, up from $1.24 billion a year earlier
  • Earnings per share also rose to 63 cents from 46 cents
  • Adjusted EPS came in at $1.21 Press release
  • Revenue grew 18% year-over-year to $12.28 billion
  • The consensus was $1.17 in adjusted EPS on sales of $11.96 billion
Jesuraj S

Leave a Comment